Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8524MR)

This product GTTS-WQ8524MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Neuroblastoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ8524MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4466MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ13076MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ3808MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ9577MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ3057MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ9085MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ10353MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ4461MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-901608
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW